Trials
1 active
6 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Arm A: Oral olorofim loading dose: 5 tablets (150 mg) to be taken twice daily at a 12-hour (± 1 hour) interval on Day 1 followed by a maintenance dose of 3 tablets (90 mg) to be taken twice daily at 12-hour (± 1 hour) intervals from Day 2 until Day 168 (± 7 days)”In the company’s words, NCT07712484 on ClinicalTrials.gov
- Tested for
- Coccidioidomycosis, Disseminated Fungal Infection, Coccidioides Infection, Coccidioides Immitis Infection, Coccidioides Posadasii Infection, Coccidioidomycosis Infection, San Joaquin Valley Fever, Valley Fever
- Main trialPhase 2
- “The purpose of this study is to test measurement tools (questionnaire about symptoms and a questionnaire about quality of life) to assess usability in the assessment of treatment effectiveness for people with disseminated coccidioidomycosis (DCM).”In the company’s words, NCT07712484 on ClinicalTrials.gov
- Other names
- F901318
- Given with
- Ambisome (Astellas)Other companies’ drugs in its trials
Coming up1
- Jun 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | Jun 2028 | A Phase II Randomized Study to Evaluate Measures for Endpoint Derivation in Patients With Progressive or Refractory Disseminated Coccidioidomycosis Treated With Olorofim Plus Baseline Standard of Care or Placebo Plus Baseline Standard of Care | |
| Phase 3Completed | 18 Nov 2025 | Olorofim Aspergillus Infection Study | |
| Phase 2Completed | 10 Feb 2023 | Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options | |
| Phase 1Completed | 15 Sep 2020 | A Biopharmaceutics Study to Assess the Pharmacokinetics of Single Oral and IV Doses of Olorofim | |
| Phase 1Completed | 24 Oct 2021 | A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment | |
| Phase 1Completed | 13 Dec 2022 | A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Renal Impairment |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026